AbCellera Biologics rated Hold amid valuation concerns despite upcoming Phase 2 trial for hot flash drug.

AbCellera Biologics Inc. remains rated Hold due to valuation concerns outweighing near-term pipeline catalysts. The company's drug ABCL635, targeting hot flashes, is advancing to a Phase 2 trial with key data expected in Q3, which could reduce risk. However, most other pipeline programs are preclinical or awaiting funding, limiting near-term revenue visibility. The current stock price seems to reflect optimistic outcomes for ABCL635, but a failed trial could cause a 30-50% drop in share price.